Sonnet BioTherapeutic News

Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Maintains $30 Price Target

BenzingaAug 23 23:37

Sonnet BioTherapeutics Analyst Ratings

BenzingaAug 23 23:37

Sonnet BioTherapeutics Analyst Ratings

BenzingaMay 28 18:55

EF Hutton: Maintains Sonnet BioTherapeutics (SONN.US) rating, adjusted from buy to buy rating, and adjusted target price from $11.00 to $7.00.

Zhitong FinanceMay 17 02:31

Sonnet BioTherapeutics Analyst Ratings

BenzingaMay 17 02:25

EF Hutton Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $7

BenzingaMay 17 02:25

Sonnet BioTherapeutics Analyst Ratings

BenzingaFeb 16 01:33

BTIG Reaffirms Their Buy Rating on Sonnet BioTherapeutics Holdings (SONN)

TipRanksJan 7 18:47

Sonnet BioTherapeutics Holdings (SONN) Gets a Buy From BTIG

TipRanksJan 2 22:49

Ladenburg Thalmann Initiates Coverage On Sonnet BioTherapeutics With Buy Rating, Announces Price Target of $7

BenzingaNov 27, 2023 22:00

Sonnet BioTherapeutics Analyst Ratings

BenzingaNov 27, 2023 21:59

Sonnet BioTherapeutics Analyst Ratings

BenzingaAug 23, 2023 16:36

Sonnet BioTherapeutics Analyst Ratings

BenzingaAug 16, 2023 22:22

Chardan Capital Keeps Their Buy Rating on Sonnet BioTherapeutics Holdings (SONN)

TipRanksAug 16, 2023 21:35

Chardan Cuts Price Target on Sonnet BioTherapeutics to $12 From $14, Keeps Buy Rating

MT NewswiresAug 16, 2023 21:32

Sonnet BioTherapeutics Holdings (SONN) Receives a Buy From EF Hutton

TipRanksJun 27, 2023 00:25

Chardan Lowers Price Target on Sonnet BioTherapeutics to $14 From $17, Keeps Buy Rating

MT NewswiresMay 11, 2023 18:23

Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $14

BenzingaMay 11, 2023 17:21

Chardan Cuts Price Target on Sonnet BioTherapeutics to $17 From $22, Anticipating Higher Future Share Count, Maintains Buy Rating

MT NewswiresApr 19, 2023 19:23

Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $17

BenzingaApr 19, 2023 18:25